4.7 Article

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

期刊

NEUROPSYCHOPHARMACOLOGY
卷 42, 期 11, 页码 2105-2113

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2017.84

关键词

-

资金

  1. Wellcome Trust
  2. Alex Mosley Charitable Trust
  3. Beckley Foundation, as part of the Beckley-Imperial Research Programme

向作者/读者索取更多资源

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据